Sagility Limited (NSE: SAGILITY, BSE: 544282) announced robust consolidated financial results for the quarter ended December 31, 2025. Revenue grew by 35.7% YoY (29.1% in constant currency). Adjusted EBITDA reached 26.0%, with a 24.2% YoY increase. Adjusted PAT also saw a healthy rise of 23.0%, reaching 16.4%. The company continues to expand its reach in the U.S. healthcare industry.
Financial Performance in Q3 FY26
Sagility Limited reported significant growth in revenue and profitability for the third quarter. Key highlights include:
- Revenue: ₹ 19,712 million (US$ 222.0 million), a 35.7% YoY increase (29.1% in constant currency).
- Organic Growth: 19.9% YoY (13.9% in constant currency).
- Adjusted EBITDA: ₹ 5,125 million (US$ 57.7 million), representing 26.0% of revenue and a 24.2% YoY increase.
- Adjusted PAT: ₹ 3,229 million (US$ 36.4 million), 16.4% of revenue, with a 23.0% YoY increase.
- Basic Earnings per Share (EPS): ₹ 0.57, a 23.9% YoY increase.
- Adjusted Basic Earnings per Share: ₹ 0.69, a 23.0% YoY increase.
Nine-Month Performance Ending December 2025
The company showcased sustained growth momentum over the nine-month period, including:
- Revenue: ₹ 51,686 million (US$ 591.8 million), a 29.2% YoY increase (24.2% in constant currency).
- Organic Growth: 18.0% YoY (13.5% in constant currency).
- Adjusted EBITDA: ₹ 13,164 million (US$ 150.7 million), representing 25.5% of revenue and a 25.3% YoY increase.
- Adjusted PAT: ₹ 8,236 million (US$ 94.3 million), 15.9% of revenue, with a 44.3% YoY increase.
- Basic Earnings per Share: ₹ 1.42, a significant 82.7% YoY increase.
- Adjusted Basic Earnings per Share: ₹ 1.76, with a 41.7% YoY increase.
Operational Highlights
As of December 31, 2025, Sagility reports:
- A workforce of 48,522 employees.
- A presence in 5 countries with 35 delivery centers.
- Recognition as an Innovator in RCM Business Process Transformation by Avasant.
- Acknowledgment as one of India’s Best Workplaces™ in Pharmaceuticals, Healthcare, and Biotech.
Source: BSE
